Latent autoimmune diabetes in adults

Type 1 Diabetes in Adults: Principles and Practice

Volumn , Issue , 2007, Pages 17-32

  Naik, R G ^a   Palmer, J P ^b  

^a BOMBAY HOSPITAL   (India)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84894062730     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (95)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complication. Part 1: Diagnosis and classification of diabetes mellitus: Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
3. Naik RG, Palmer JP. Late-onset type 1 diabetes. Current Opin Endocrinol Diabetes 1997; 4: 308-315.
4. Bottazzo G-F, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; ii: 1279-1282.
5. MacCuish AC, Irvine WJ, Barnes EW, et al. Antibodies to pancreatic islet cells in insulindependent diabetics with coexistent autoimmune disease. Lancet 1974; ii: 1529-1531.
6. Kuzuya T, Matsuda A. Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Diabetes Care 1997; 20(2): 219-220.
7. Service EJ, Rizza RA, Zimmerman BR, et al. The classification of diabetes by clinical and C-peptide criteria: A prospective population-based study. Diabetes Care 1997; 20(2): 198-201.
8. Van der Auwera B, Van Waeyenberge C, Schuit F, et al. DRB1*0403 protects against IDDM in Caucasians with the high-risk heterozygous DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201 genotype. Belgian Diabetes Registry. Diabetes 1995; 44(5): 527-530.
9. Neifing JL, Greenbaum CJ, Kahn SE, et al. Prospective evaluation of beta-cell function in insulin autoantibody-positive relatives of insulin-dependent diabetic patients. Metabolism 1993; 42(4): 482-486.
10. McCulloch DK, Palmer JP. The appropriate use of B-cell function testing in the preclinical period of type 1 diabetes. Diabet Med 1991; 8(9): 800-804.
11. Hathout EH, Thomas W, El-Shahawy M, et al. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 2001; 107(6): E102.
12. Libman I, Pietropaolo M, Arslanian S, et al. Risk factors associated with type 2 diabetes in youngsters with type 1a (autoimmune) diabetes: Does it matter? Diabetes 2001; 50(S2): A39.
13. Pihoker C, Brooks-Worrell BM, Greenbaum CJ, et al. Impact of islet reactive T cells and autoantibodies on clinical diagnosis of type 1, type 2, or atypical diabetes in children. Diabetes 2000; 49(S1): A409.
14. Juneja R, Palmer JP. Type 1 1/2 diabetes: Myth or reality. Autoimmunity 1999; 29: 65-83.
15. Karjalainen J, Salmela P, Ilonen J, et al. A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 1989; 320(14): 881-886.
16. Lorenzen T, Pociot F, Hougaard P, et al. Long-term risk of IDDM in first-degree relatives of patients with IDDM. Diabetologia 1994; 37(3): 321-327.
17. Irvine WJ, Gray RS, McCallum CJ, et al. Clinical and pathogenic significance of pancreatic-isletcell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1977; i: 1025-1027.
18. Chiu HK, Tsai EC, Juneja R, et al. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res Clin Pract, 2007; 77(2): 237-244.
19. Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: “double” diabetes? Pediatr Diabetes 2003; 4(1): 110-113.
20. Naik RG, Palmer JP. Latent autoimmune diabetes in adults (LADA). Rev Endocr Metab Disord 2003; 4: 233-241.
21. Palmer JP, Hampe CS, Chiu H, et al. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005; 54: S62-S7.
22. Borg H, Gottsäter A, Landin-Olsson M, et al. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001; 86: 3032-3038.
23. Urakami T, Miyamoto Y, Matsunaga H, et al. Serial changes in the prevalence of islet cell antibodies and islet cell antibody titer in children with IDDM of abrupt or slow onset. Diabetes Care 1995; 18: 1095-1099.
24. Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993; 16(5): 780-788.
25. Juneja R, Hirsch IB, Naik RG, et al. Islet cell antibodies and glutamic acid decarboxylase antibodies but not the clinical phenotype help to identify type 1 1/2 diabetes in patients presenting with type 2 diabetes. Metabolism 2001; 50: 1008-1013.
26. Nakanishi K, Kobayashi T, Miyashita H, et al. Relationships among residual beta cells, exocrine pancreas, and islet cell antibodies in insulin-dependent diabetes mellitus. Metabolism 1993; 42(2): 196-203.
27. Yeung V, Chan JCN, Chow CC, et al. Antibodies to glutamic acid decarboxylase (anti-GAD) in Chinese IDDM patients. In: 15th International Diabetes Fedration Congress Proceedings, Kobe, Japan, 1994. p. 432.
28. Zimmet PZ. The pathogenesis and prevention of diabetes in adults: Genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1050-1064.
29. Anonymous. Insulin-dependent? Lancet 1985; 2: 809-810.
30. Gleichmann H, Zorcher B, Greulich B, et al. Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults. Diabetologia 1984; 27: 90-92.
31. Palmer JP, Hirsch IB. What’s in a name: Latent autoimmune diabetes in adults, type 1.5, adultonset, and type 1 diabetes. Diabetes Care 2003; 26: 536-538.
32. Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48: 2206-2212.
33. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and ß-cell function in human subjects: Evidence for a hyperbolic function. Diabetes 1993; 42: 1663-1672.
34. Kahn SE. The importance of ß-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 4047-4058.
35. Krischer JP, Cuthbertson DD, Yu L, et al. The Diabetes Prevention Trial-Type 1 Study Group: Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 103-108.
36. Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996; 9(3): 379-383.
37. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45(7): 926-933.
38. Rowley MJ, Mackay IR, Chen QY, et al. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 1992; 41: 548-551.
39. Palmer JP. What is the best way to predict IDDM? Lancet 1994; 343(8910): 1377-1378.
40. Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000; 342(5): 301-307.
41. Lernmark A. Rapid-onset type 1 diabetes with pancreatic exocrine dysfunction. N Engl J Med 2000; 342(5): 344-345.
42. Park Y, Lee HK, Koh CS, et al. The low prevalence of immunogenetic markers in Korean adult-onset IDDM patients. Diabetes Care 1996; 19(3): 241-245.
43. Fukui M, Nakano K, Shigeta H, et al. Antibodies to glutamic acid decarboxylase in Japanese diabetic patients with secondary failure of oral hypoglycaemic therapy. Diabet Med 1997; 14(2): 148-152.
44. Gottsater A, Landin Olsson M, Fernlund P, et al. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993; 16(6): 902-910.
45. Hagopian WA, Karlsen AE, Gottsater A, et al. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64 K autoantibody positivity at onset predicts diabetes type. J Clin Invest 1993; 91(1): 368-374.
46. Kasuga A, Maruyama T, Ozawa Y, et al. Antibody to the Mr 65,000 isoform of glutamic acid decarboxylase are detected in non-insulin-dependent diabetes in Japanese. J Autoimmun 1996; 9(1): 105-111.
47. Willis JA, Scott RS, Brown LJ, et al. Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus. Diabetes Res Clin Pract 1996; 33(2): 89-97.
48. Zimmet P. Antibodies to glutamic acid decarboxylase in the prediction of insulin dependency. Diabetes Res Clin Pract 1996; 34 Suppl(1): S125-S31.
49. Turner R, Stratton I, Horton V, et al. UKPDS 25. Autoantibodies to islet-cell cytoplasma and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350: 1288-1293.
50. Borg H, Marcus C, Sjoblad S, et al. Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes. Acta Paediatr 2000; 89: 46-51.
51. Borg H, Gottsäter A, Fernlund P, et al. A 12-year prospective study of the relationship between islet antibodies and ß-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002; 51: 1754-1762.
52. Seissler J, De Sonnaville JJJ, Morgenthaler NG, et al. Immunological heterogeneity in type 1 diabetes: Presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998; 41: 891-897.
53. Falorni A, Gambelunghe G, Forini F, et al. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J Clin Endocrinol Metab 2000; 85(1): 309-316.
54. Hampe CS, Kockum I, Landin-Olsson M, et al. GAD65 antibody epitope patterns of patients with Type 1.5 differ from that of type 1 diabetes patients. Diabetes Care 2002; 25: 1481-1482.
55. Padoa CJ, Banga JP, Madec A-M, et al. Recombinant Fab of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 2003; 52: 2689-2695.
56. Kobayashi T, Tanaka S, Okubo M, et al. Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly proressive and acute-onset type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 4768-4775.
57. Hillman M, Törn C, Thorgeirsson H, et al. IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes. Diabetologia 2004; 47: 1984-1989.
58. Brooks-Worrell B, Dosch HM, Herold K, et al. Marked differences in T cell reactivity in recently diagnosed type 1 diabetes patients versus controls. In: 12th International Congress of Immunology and 4th Annual Conference of the Federation of Clinical Immunology Societies, Montreal, Canada, 2004.
59. Brooks-Worrell BM, Starkebaum GA, Greenbaum C, et al. Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J Immunol 1996; 157: 5668-5674.
60. Brooks-Worrell BM, Juneja R, Minokadeh A, et al. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999; 48(5): 983-988.
61. Brooks-Worrell B, Gersuk VH, Greenbaum C, et al. Intermolecular antigen spreading occurs during the pre-clinical period of human type 1 diabetes. J Immunol 2001; 166: 5265-5270.
62. Behme MT, Dupré J, Harris SB, et al. Insulin resistance in latent autoimmune diabetes of adulthood. Ann N Y Acad Sci 2003; 1005: 374-377.
63. Zimnan B, Kahn SE, Haffner SM, et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004; 53: 3193-3200.
64. Chiu HK, Palmer JP. Autoimmune diabetes: More than just one flavor? J Endocrinol Invest 2004; 27: 480-484.
65. Sanjeevi CB, Gambelunghe G, Falorni A, et al. Genetics of latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002; 958: 107-111.
66. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48(1): 150-157.
67. Groop L, Miettinen A, Groop PH, et al. Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes. Diabetes 1988; 37(1): 99-103.
68. Cosentino A, Gambelunghe G, Tortoioli C, et al. CTLA-4 gene polymorphism contributes to the genetic risk for latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002; 958: 337-340.
69. Cerrone GE, Caputo M, Lopez AP, et al. Variable number of tandem repeats of the insulin gene determines susceptibility to latent autoimmune diabetes in adults. Mol Diagn 2004; 8: 43-49.
70. Törn C, Gupta M, Zake LN, et al. Heterozygosity for MICA5.0/MICA5.1 and HLA-DR3-DQ2/DR4-DQ8 are independent genetic risk factors for latent autoimmune diabetes in adults. Hum Immunol 2003; 64: 902-909.
71. Vatay Á, Rajczy K, Pozsonyi É, et al. Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus. Immunol Lett 2002; 84: 109-115.
72. Hossźufalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of Latent Autoimmune Diabetes in Adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 2003; 26: 452-457.
73. Christie M, Delovitch TL. Persistence of antibodies to a 64,000-Mr islet cell protein after onset of type I diabetes. Diabetes 1990; 39: 653-659.
74. Marner B, Agner T, Binder C, et al. Increased reduction in fasting C-peptide is associated with islet cell antibodies in type 1 (insulin-dependent) diabetic patients. Diabetologia 1985; 28: 875-880.
75. Carlsson A, Sundkvist G, Groop L, et al. Insulin and glucagon secretion in patients with slowly progressive autoimmune diabetes (LADA). J Clin Endocrinol Metab 2000; 85: 76-80.
76. Raz I, Elias D, Avron A, et al. B-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): Arandomized, double blind, phase II trial. Lancet 2001; 358: 1749-1753.
77. Tarn AC, Thomas JM, Dean BM, et al. Predicting insulin-dependent diabetes. Lancet 1988; i: 845-850.
78. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-1698.
79. Bertrand S, De Paepe M, Vigeant C, et al. Prevention of adoptive transfer in BB rats by prophylactic insulin treatment. Diabetes 1992; 41: 1273-1277.
80. Gotfredsen CF, Buschard K, Frandsen EK. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985; 28: 933-935.
81. Gottlieb PA, Handler ES, Appel MC, et al. Insulin treatment prevents diabetes mellitus but not thyroiditis in RT6-depleted diabetes resistant BB/Wor rats. Diabetologia 1991; 34(5): 296-300.
82. Atkinson MA, Maclaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39(8): 933-937.
83. Muir A, Peck A, Clare Salzler M, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 1995; 95(2): 628-634.
84. Thivolet CH, Goillot E, Bedossa P, et al. Insulin prevents adoptive cell transfer of diabetes in the autoimmune non-obese diabetic mouse. Diabetologia 1991; 34(5): 314-319.
85. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989; 320(9): 550-554.
86. Kobayashi T, Nakanishi K, Murase T, et al. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45(5): 622-626.
87. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med. 1998; 128: 517-523.
88. Kobayashi T. Multicenter prevention trial of slowly progressive IDDM with small dose of insulin (the Tokyo Study). Diabetes Metab Res Rev 2001; 17 (Suppl.): S29.
89. Kobayashi T, Maruyama T, Shimada A, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann N Y Acad Sci 2002; 958: 117-130.
90. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346: 1685-1691.
91. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993; 341: 927-928.
92. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19(4): 238-246.
93. Ludvigsson J, Casas R, Vaarala O, et al. The Swedish GAD-vaccination Trial: Outcomes of a phase II safety and efficacy trial with Diamyd TM for preservation of beta cell function in children with T1D. Oral Presentation (OP 41) at the 42nd Annual Meeting of EASD; Copenhagen, Malmoe, Denmark, Sweden, September 14-17, 2006.
94. Palmer JP. Immunomodulatory therapy of human type 1 diabetes: Lessons from the mouse. J Clin Invest 2001; 108: 31-33.
95. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.